LY3177833 |
| Catalog No.GC19233 |
LY3177833 is an CDC7 and pMCM2 inhibitor extracted from patent US 20140275131and patent WO 2014143601 A1 compound example 4; has IC50 values of 3.3 nM and 290 nM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1627696-51-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LY3177833 is a CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively[1].
LY3177833 (Compound example 4; 10.4-31.2 mg/kg; oral gavage; twice a day; for 2 weeks; female athymic Balb/c nude mice with SW620 cells) treatment causes significant tumor regression in a dosedependent manner. Also, no significant tumor growth is observed for 2 weeks after dosing cessation[1].
References:
[1]. DALLY, Robert Dean, et al. CDC7 Inhibitors. 18 September 2014. WO2014143601A1.
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *